Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
CONNECT WITH US
Get in touch
Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
Find us: PharmNovo AB, Medicon Village AB, Scheeletorget 1, SE-223 81 Lund, Sweden
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read moreFollowing the successful completion of our phase I study, we are pleased to announce our collaboration with WCT, Worldwide Clinical Trials, as the phase IIa study of our drug candidate PN6047. This partnership underscores our commitment to developing solutions for neuropathic pain. In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep. PN6047 offers a targeted approach to alleviate this condition, aiming to improve the overall pain experience. Insights on its efficacy will aid in designing subsequent phase IIb/III studies.
Read moreIn the pharmaceutical development arena, experts like Jesper Kjerulff stand out. As Global project lead and Chief operations officer (COO) of PharmNovo, Jesper Kjerulff is instrumental in propelling the company's groundbreaking project, PN6047, and advancing the field of neuropathic pain management.
Read moreIn August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read more
